Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

Israeli biotech company KAHR raises $12 million Series B funds

Drug development company KAHR Medical Ltd has raised $12 million in a Series B financing round from new investors Korea Investment Partners, Mirae Asset Venture Investment and DSC Investment, along with an existing investor, Flerie Invest AB. The Jerusalem-based developer of cancer and auto-immune treatments plans to use the new financing primarily to fund the clinical development of KAHR’s lead product, KAHR-102, which recently received regulatory approval in Israel to initiate a Phase-I/IIa trial in lymphoma, as well as pre-clinical development of KAHR-101 and new pipeline programs. RM Global Partners advised KAHR on the financing. KAHR was represented by Pearl Cohen Zedek Latzer Baratz law firm.


VC Deals,biotech,DSC Investment,Flerie Investment,KAHR Medical,Korea Investment Partners,Mirae Asset Venture Investment,RM Global Partners